Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

Phase 2

Completed

• Conditions: Parkinson's Disease
• Interventions: Drug: Mesenchymal Stem Cells; Drug: Placebo

• Registration Number: NCT04506073
• Lead Sponsor: The University of Texas Health Science Center, Houston

Brief Summary

The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).

Detailed Description

Single site phase IIa study of allogeneic MSC in a double blind randomized control trial as disease modifying therapy for PD. The design includes three treatment arms with 45 patients.

Study Timeline

• Study First Submitted: 2020-07-16
• Study First Submitted QC: 2020-08-06
• Study First Posted: 2020-08-10
• Study Start: 2020-11-09
• Primary Completion: 2023-07-30
• Study Completion: 2023-07-30
• Status Verified: 2024-07
• Disposition First Submitted: 2024-07-17
• Disposition First Posted: 2024-07-18
• Last Update Submitted: 2024-07-24
• Last Update Posted: 2024-07-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Diagnosis of Parkinson's disease by the UK brain bank criteria including the presence of 2 cardinal signs of PD plus bradykinesia.
• Mild microsomia to anosmia.
• A modified Hoehn and Yahr stage of 3 or less.
• Date of diagnosis of PD between 3 to 10 years
• Robust response to dopaminergic therapy.

Read More

Exclusion Criteria

• Atypical, vascular, or drug-induced Parkinsonism.
• An atypical DAT scan or MRI supporting an alternative explanation for PD symptoms.
• Patient not on levodopa containing medications.
• Clinical features of psychosis or refractory hallucinations.
• A Montreal Cognitive Assessment (MoCA) score of less than 25.
• Uncontrolled seizure disorder.
• Abnormal Kidney and liver function.
• Presence of clinically refractory orthostatic hypotension at the screening or baseline visit.
• Body mass index of greater than or equal to 35.
• Cardiac disease: History of congestive heart failure, clinically significant bradycardia, presence of 2nd, or 3rd-degree atrioventricular block.
• Pulmonary disease: COPD with oxygen-requirement at rest or with ambulation; or moderate to severe asthma.
• Active malignancy or diagnosis of malignancy within 5 years prior to the start of screening
• Any current suicidal ideation or behaviors.
• Any diagnosis of autoimmune disease or immunocompromised state
• History of medium or large size vessel cerebrovascular accidents.
• History of traumatic brain injury with loss of consciousness and residual neurologic symptoms.
• Major surgery within the previous 3 months or planned in the ensuing 6 months.
• History of use of an investigational drug within 90 days prior to the screening visit.
• History of brain surgery for PD.
• Substance abuse disorder.
• Active anticoagulation treatment and/or abnormal INR.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Mesenchymal Stem Cells and Placebo	Mesenchymal Stem Cells	2 infusions of 10 X 10\^6 MSC/kg and 1 placebo infusion, all doses administered 4 months apart.
Mesenchymal Stem Cells and Placebo	Placebo	2 infusions of 10 X 10\^6 MSC/kg and 1 placebo infusion, all doses administered 4 months apart.
Mesenchymal Stem Cells	Mesenchymal Stem Cells	3 infusions of 10 X 10\^6 MSC/kg administered every 4 months.
Placebo	Placebo	3 placebo doses administered every 4 months.

Primary Outcome Measures

Name	Time	Method
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale	Week 78 follow-up

Secondary Outcome Measures

Name	Time	Method
Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)	Baseline,week 7,week 20,week 29,week 39,week 52,week 78
Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)	Baseline,week 7,week 20,week 29,week 39,week 52,week 78
Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)	Baseline,week 7,week 20,week 29,week 39,week 52,week 78
Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)	Baseline,week 29,week 78
Global measurement of disability as measured by the change in the screening "Off" modified Hoehn and Yahr (H&Y)	Baseline,week 7,week 20,week 29,week 39,week 52,week 78
Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).	Baseline,week 29,week 78
Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)	Baseline,week 7,week 20,week 29,week 39,week 52,week 78	The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool that evaluates suicidal ideation and behavior. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Exclusionary criteria views 1 or more positive answers in the last month as not eligible for participation. In follow up, one positive response requires further investigation.
Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.	Baseline,week 7,week 20,week 29,week 39,week 78	Examples of these are IL-1beta, IL-6, TNF-alpha, COX-2 and PGE-2. These are measured by Magnetic Bead Panel - Multiplex Assay or ELISA, allowing for specificity in the blood.
Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.	Baseline,week 7,week 20,week 29,week 39,week 78	Examples of these are CCL2 (MCP-1), CCL7 (MCP-3), CCL11 (Eotaxin) CCL2 (MDC), CXCL10 (IP-10), CX3CL1 (Fractalkine). These will be measured by Magnetic Bead Panel - Multiplex Assay or ELISA, allowing for specificity in the blood.
Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors	Baseline,week 7,week 20,week 29,week 39,week 78	Examples of these are Glial Derived Neurotrophic Factor, Brain Derived Neurotrophic Factor and Vascular Epidermal Growth Factor . These will be measured by ELISA specific to blood and CSF.
Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters	Baseline,week 7,week 20,week 29,week 39,week 78	Examples of these are homovanillic acid and 5-hydroxytryptamine. These will be measured in CSF and blood by ELISA.
Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)	Basleline,week 29,week 39,week 78
Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid	Baseline,week 39
Safety and tolerability as measured by serious adverse reactions.	Baseline,week 7,week 20,week 29,week 39,week 78
Safety and tolerability as measured by immunologic responses.	Baseline,week 7,week 20,week 29,week 39,week 78	Donor specific antibodies (DSA) in serum of patients will be measured and compared to baseline to determine if there is a development of antibody response to donor HLA (human leukocyte antigen). This will determine if there is a possibility of anti-donor alloimmune response after the first or second infusion of MSC, which might lead to a subsequent antibody-mediated rejection (AMR) with the following infusion. Testing will be done at the these time points to determine if 2nd or 3rd infusions will continue.
Motor function as measured by the Timed-Up-and-Go (TUG) scale	Baseline,week 7,week 20,week 29,week 39,week 52,week 78	This test uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. A longer duration of time indicates a worse outcome
Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)	Baseline,week 7,week 20,week 29,week 39,week 52,week 78	The Geriatric Depression Scale Short form (GDS-SF) is a 15-item screening tool that is used to identify depression in older adults. Answers indicating depression are in bold and italicized; score one point for each bold one selected. A score of 0 to 5 is normal. A score greater than 5 suggests depression and requires evaluation, whereas a score of 10 or greater would require evaluation for treatment .
Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)	Baseline,week 7,week 20,week 29,week 39,week 52,week 78
Measurement of putative paracrine mechanism of MSCs using neuroimaging	Baseline,week 29,week 78

Trial Locations

Locations (1)

The University of Texas Health Science Center at Houston; 🇺🇸 Houston, Texas, United States